Hematopoietic Stem Cell Transplantation (HSCT) is an effective treatment for malignant hematological tumors. One of the key factors determining the success of HSCT is Human Leukocyte Antigen (HLA) matching. If the HLA of the donor and the patient (recipient) do not match, severe rejection may occur, even endangering life.

On January 27, 1964, Academician Lu Daopei, the "founder of bone marrow transplantation in China," successfully performed Asia's first and the world's fourth allogeneic bone marrow transplantation at Peking University People's Hospital. This opened the era of hematopoietic stem cell transplantation (HSCT) for treating hematological diseases in China, bringing new hope to countless hematology patients.

Orlando, USA, Dec 6-9, 2025 – The 67th American Society of Hematology (ASH) Annual Meeting, one of the most influential global hematology events, convened top scholars and clinical experts from over 100 countries. The meeting served as a premier platform for exchanging groundbreaking research, diagnostic and treatment concepts, and practical experience, collectively shaping the future of hematology.